Word: transplanted
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...army of patients to portray a man motivated by nothing but the Hippocratic oath. "I'd go to the ends of the earth for him,'' says Charles Fiske of Bridgewater, Massachusetts, whose 11-month-old daughter Jamie in 1982 became the world's youngest recipient of a successful liver transplant performed by Najarian. Scott Jameson of Minneapolis, Minnesota, who recently marked the 25th anniversary of his kidney transplant, is already considering what he'd like to tell the jury. "I've seen one side of the man," he says, "and he's been nothing but good...
...patient survival rates improved, other surgeons clamored to get hold of the potion. Between 1970, when Najarian obtained permis-sion from the FDA to produce and use the compound on an experimental basis, and 1992, when the FDA shut down the operation, Minnesota ALG was shipped to 175 transplant centers around the world and was used by more than 50,000 patients. Along the way, it generated an estimated $80 million in revenues, enough to finance a $13 million production facility on the University of Minnesota's St. Paul campus...
...cost, was making a handsome profit. According to the indictment, the two co-conspirators were driven by a desire to enhance Najarian's power and prestige. The surgeon denounces that allegation as ludicrous. "I didn't need to enhance my power and prestige. I was one of the original transplant surgeons in the U.S. and, in fact, the world...
...what Najarian was doing was so wrong, his supporters ask, why did the FDA and the university wait so long to act? "The paper work [required by the FDA] didn't get done," observes transplant surgeon David Sutherland, Najarian's longtime colleague. "But the paper work hadn't been getting done for more than 20 years." Moreover, the sale and success of alg were never a secret. From the beginning, says University of Minnesota medical historian Leonard Wilson, Najarian told the FDA that he intended to produce the drug for more than his own use. Says Wilson: "The FDA would...
...Fellow transplant surgeons speculate that the FDA crackdown may have been triggered by complaints from commercial drug companies. These companies, the thinking goes, were annoyed that their university-based competitor was selling an experimental drug as if it had been approved for full marketing. Or it may be that regulators, who sent letters to Najarian complaining of infractions, were unwilling to cut off the supply of a drug that filled such a desperate need. Whatever the reason, by the time the fda barred ALG production in 1992, two drugs capable of taking its place had come on the market...